The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias
Abstract
We investigated whether angiotensin II receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACE-Is) are more strongly associated with Alzheimer's disease (AD), vascular dementia (VaD), and other dementias, than other anti-hypertensive drugs. We conducted a nested case-control analysis within the UK general practice research database, with prospectively recorded anti-hypertensive prescribing data. We sampled cases aged ≥60 years and diagnosed between 1997–2008 (5,797 with AD, 2,186 with VaD, 1,214 with unspecified/other dementia) which were matched to up to four controls by age, general practice and gender. We computed odds-ratios and dose response effects for AD, vascular and unspecified/other dementia, comparing those prescribed ARBs or ACE-Is for at least six months with patients prescribed other anti-hypertensives. We controlled for matching factors, co-morbidities, smoking status, an area measure of socioeconomic status, consultation rate and blood pressure and accounted for reverse causality by introducing time-lags of up to eight years prior to diagnosis/index date. Patients diagnosed with AD, vascular and unspecified/other dementia had fewer prescriptions for ARBs and ACE-Is. Inverse associations with AD were strongest for ARBs (odds-ratio; 0.47, 95%CI, 0.37–0.58) compared with ACE-Is (odds-ratio; 0.76, 95%CI, 0.69–0.84) (p difference < 0.001). Associations of ARBs with AD were stronger than for vascular dementia (p difference = 0.01) and unspecified/other dementia (p difference = 0.23). There were inverse dose-response relationships between ARBs and ACE-Is with AD (both p trend < 0.01). The inverse association of ACE-Is with AD diminished when using longer time lags but the ARB-AD association persisted. Patients with AD were around half as likely to be prescribed ARBs. Further randomized controlled trial evidence is required to rigorously test these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, they can be used as a supplemental agent of antidepressants[70].”
From Neuroinflammation and cytokine abnormality in major depression: cause or consequence in that illness? (2016) · cites this paper as [70]
Citations
Cites
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,837
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
Validity of diagnostic coding within the General Practice Research Database: a systematic review
Khan, N., Harrison, S., & Rose, P. W. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x483562 · Cited by 702
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology
Salas, M., Hotman, A., & Stricker, B. H. C. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009758 · Cited by 472
Miners, J. S., Baig, S., Palmer, J. C., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 393
Self-citationBuée, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 331
Shapiro, S. (1997) · PubMed · Cited by 299
Cited by
Sorted by citations
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 307
Self-citationJeon, S. W., & Kim, Y. K. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i3.283 · Cited by 247
Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions
Abeysinghe, A. A. D. T., Deshapriya, S., & Udawatte, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117996 · Cited by 259
Kelleher, R. J., & Soiza, R. L. (2013) · Europe PMC (PubMed Central) · Cited by 232
Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Jiang, T., Yu, J., Tian, Y., & Tan, L. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990155 · Cited by 231
Metadata
- Authors
- Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M.
- Affiliations
- University of Bristol (GB)
- Frenchay Hospital (GB)
- School of Social and Community Medicine, Faculty of Medicine and Dentistry, University of Bristol, Canynge Hall, Bristol, UK
- Corresponding author
- Kehoe, Patrick G
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2011-10-04
- Volume
- 26
- Issue
- 4
- Pages
- 699-708
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1828947725
- Cited by
- 212
- References
- 41
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 12 · 2023: 9 · 2022: 9 · 2021: 16 · 2020: 17 · 2019: 8 · 2018: 14 · 2017: 12 · 2016: 28 · 2015: 15 · 2014: 18 · 2013: 24 · 2012: 19
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Funders
- North Bristol NHS Trust
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- angiotensin receptor blockers, ACE inhibitors
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Data Interpretation, Statistical, Dementia, Dose-Response Relationship, Drug, Female, United Kingdom, Humans, Male, Socioeconomic Factors, Dementia, Vascular, Case-Control Studies, Databases, Factual, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
